The Low-Amylose Diet: Starving Mold Inflammation at Its Source

In the spring of 2019, a woman in her late thirties named Rachel — a former endurance athlete, PhD candidate, still technically functional but fading by the month — sat across from her third specialist in two years. She had already been told she had chronic fatigue syndrome. She had been told she was depressed. She had been told her bloodwork was “unremarkable,” a word that would be funny if it weren’t so exhausting to hear. What she actually had was Chronic Inflammatory Response Syndrome from mold exposure, and the biomarkers to prove it: MMP-9 at over 800 ng/mL, VEGF suppressed to near-undetectable, C4a elevated by a factor of four. She had found a CIRS-literate physician, started cholestyramine, cleared her MARCoNS, relocated from the water-damaged apartment. She was doing everything right. Six weeks in, her MMP-9 had barely moved. And every single day, she was eating low-amylose foods — or so she thought. What she hadn’t touched was the stack of gluten-free crackers on her counter, the brown rice with every dinner, and the “healthy” oatmeal she’d been eating for a decade.

This article is about the low-amylose diet: what it is, why it works, exactly how to execute it, and why so many people who know they need it still manage to fail at it. CIRS biomarkers stuck — MMP-9 won’t drop, VEGF won’t rise despite doing everything else in the protocol — the thing feeding the fire is probably on the plate.

The Body: What Mold Does to Your Biochemistry Before You Touch a Single Forkful

Before diet’s role in CIRS recovery makes sense, the prerequisite is understanding what mold exposure has already done to the body — specifically to the regulatory systems governing inflammation, immune function, and metabolic response. Because the low-amylose diet is not a general health recommendation. It’s a targeted intervention in a specific, documented physiological state that mold has created. Without understanding that state, the protocol makes no sense, and sticking to it with the rigor it requires becomes nearly impossible.

CIRS — Chronic Inflammatory Response Syndrome — is a multisystem illness caused by biotoxins produced by mold, bacteria, and other microorganisms in water-damaged buildings. The mechanism is well-documented: biotoxins from species like Stachybotrys chartarum, Aspergillus, and Penicillium enter the body through inhalation, and in the roughly 25 percent of the population with specific HLA-DR immune gene variants, these biotoxins are not cleared. The immune system cannot tag them for removal because they lack the protein coat that triggers normal antibody response. They circulate. They bind to receptors. They activate an innate immune response that, in people with susceptible genetics, never turns off. The result is a chronic, systemic inflammatory state driven by dysregulated cytokines, elevated matrix metalloproteinase-9 (MMP-9), and suppressed vascular endothelial growth factor (VEGF).

Here’s why this matters at the dinner table.

The inflammatory machinery CIRS has activated does not operate in isolation. It’s sensitive — profoundly so — to metabolic inputs. Specifically, to insulin. And insulin is produced in direct response to dietary carbohydrates, particularly a class called amylose. A CIRS patient sitting down to a bowl of white rice or a plate of pasta is not simply eating dinner. They’re sending an insulin surge into a biochemical environment primed, by mold-driven immune activation, to interpret that surge as a signal to amplify inflammation. The cytokines go up. The MMP-9 goes up. The VEGF stays suppressed. The patient feels it as the familiar post-lunch cognitive crash, the afternoon fatigue, the brain fog that returns despite having left the moldy building months ago.

This is the fundamental insight driving the dietary component of CIRS recovery: the building may be gone, but the inflammatory fuel line is still running. The substrate is still getting supplied. Three times a day. Without anyone knowing it, in many cases, because nobody explained the mechanism in terms that made it actionable.

The Shoemaker Protocol places dietary intervention at Steps 7 and 8 of an 11-step sequential treatment framework — not because diet is unimportant, but because earlier steps (binder therapy, MARCoNS treatment, nasal colonization clearance) must be completed first for the dietary intervention to have full effect. A patient still living in a water-damaged building who eliminates amylose will see modest benefit. A patient who has addressed environmental exposure, started binder therapy, and then implements the dietary changes will see MMP-9 move meaningfully within 30 days. The sequence matters. The diet, in its correct sequential position, is not an optional add-on. It’s the step that makes the difference between plateauing and completing recovery.

Understanding the body’s current state — not as a failure state, but as a specific, mappable biochemical situation with specific, targeted interventions — is the framing that makes this protocol executable. Nobody is sick because they’re weak or unlucky. A specific environmental exposure created a specific physiological state, and that state is fuel-dependent in a specific way dietary change directly addresses. This is not complicated. It is, however, precise — and precision is what the rest of this article provides.

For a broader look at how mold wreaks havoc on your body and mind, including the neurological mechanisms most people never hear about, that piece covers the terrain in depth. This piece narrows focus to the dietary lever specifically — the one under direct control every single day, three times a day, starting with the next meal.

The Science: Amylose, Insulin, and the MMP-9 Amplification Loop

This section is the most important one. Not the protocol. Not the food list. This. Understanding the mechanism — genuinely understanding it, not just nodding along at a summary — is what makes the difference between executing this protocol with precision and treating it like a generic wellness diet followed loosely, wondering afterward why the biomarkers haven’t moved.

• Start with starch chemistry. Dietary starch is composed of two molecules: amylopectin and amylose. Amylopectin is a branched-chain polysaccharide. Because its structure is branched, digestive enzymes (primarily alpha-amylase) have many simultaneous access points, and the glucose release is relatively gradual. Amylose is different. It’s a straight-chain polysaccharide with a tight helical structure that partially resists enzymatic digestion — but when it does break down, it releases glucose rapidly. The foods highest in amylose are the staples of every Western diet: white bread, white rice, white potatoes, corn in all forms, and pasta. These foods produce the most rapid and pronounced post-meal glucose spikes of any dietary carbohydrate category. That glucose spike is the ignition event for everything that follows.
• Now the insulin mechanism. Elevated blood glucose triggers pancreatic beta cells to secrete insulin. In a healthy metabolic state, this is normal and transient physiology: insulin rises, glucose enters cells, insulin falls, and the whole cycle completes in under two hours. In a CIRS patient, the post-meal insulin spike lands in a biochemical environment fundamentally altered by months or years of chronic biotoxin-driven immune activation. Specifically, the cytokine environment — already flooded with TGF-beta, IL-1 beta, IL-6, and TNF-alpha from the mold-triggered immune response — gets amplified by the insulin surge. Insulin activates the NF-kB transcription factor. NF-kB is a master regulator of inflammatory gene expression, and in a CIRS patient, it’s already running hot. The insulin surge fans it further. The cytokine output increases. The inflammatory cascade deepens. The post-meal cognitive crash is not a coincidence. It’s a biochemical event with a predictable mechanism and a measurable duration.
• MMP-9: where this becomes clinically visible. Matrix metalloproteinase-9 is a zinc-dependent enzyme that degrades extracellular matrix proteins — the structural scaffolding of connective tissues throughout the body. In CIRS, MMP-9 is chronically elevated because the biotoxin-driven inflammatory cascade directly upregulates its expression. The consequences of this chronic elevation are not subtle: MMP-9 degrades the blood-brain barrier, accelerating the entry of inflammatory molecules and biotoxins into the central nervous system. It degrades joint cartilage and connective tissue, contributing to the musculoskeletal pain that characterizes CIRS. It degrades the lining of blood vessels, compromising vascular integrity and contributing to cardiovascular symptoms.

The dietary connection to MMP-9 is direct and acute. Insulin signaling activates NF-kB, and NF-kB drives MMP-9 gene expression. Post-prandial hyperinsulinemia — the insulin spike after a high-carbohydrate meal — produces a measurable, near-immediate elevation in circulating MMP-9 activity. Not a theoretical relationship. It’s documented in the peer-reviewed literature and observable in the biomarker data of CIRS patients who eat high-amylose meals while on the protocol. Three high-amylose meals per day equals three daily MMP-9 amplification events. The binder is running. The nasal protocol has been completed. But the dietary input is re-triggering the inflammatory enzyme at every meal. Which is why the biomarkers don’t move.

VEGF suppression: the oxygen delivery problem. Vascular endothelial growth factor is essential for maintaining the capillary network that delivers oxygen to every tissue in the body, including the brain. In CIRS, VEGF is frequently suppressed below functional levels. Part of this suppression is direct: elevated TGF-beta (a hallmark cytokine of CIRS) inhibits VEGF signaling at the receptor level. Part of it is indirect: the chronic inflammatory environment insulin is amplifying further antagonizes VEGF expression. The clinical result is a body in which oxygen delivery to peripheral tissues and the brain is compromised — contributing directly to the profound fatigue, exercise intolerance, and cognitive impairment CIRS patients experience and that often persist even after environmental exposure has been addressed. The dietary intervention addresses VEGF indirectly by reducing the insulin-driven cytokine amplification that’s suppressing it, allowing VEGF to recover toward normal range as the inflammatory load decreases.

The omega-3 mechanism is the second half of this biochemistry. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) — the long-chain omega-3 fatty acids found in cold-water fish and quality fish oil — are precursors for lipid mediators called resolvins and protectins. These molecules are not simply anti-inflammatory in the generic “fish oil is healthy” sense. They’re active resolution signals. Resolvin E1, derived from EPA, and protectin D1, derived from DHA, actively terminate inflammatory cascades and initiate the tissue repair process that follows. This is mechanistically distinct from what anti-inflammatory drugs do: NSAIDs suppress the production of inflammatory mediators but do not generate resolution signals. EPA and DHA do both — reduce the amplitude of the inflammatory cascade and signal the immune system to stand down and begin repair. In the context of CIRS, where the inflammatory cascade has been running for months or years without resolution, this distinction is clinically significant.

EPA also directly competes with arachidonic acid — the omega-6 fatty acid that serves as the primary precursor for pro-inflammatory prostaglandins and leukotrienes — for the same enzymatic pathways (COX-2 and 5-LOX). Abundant EPA in the diet means less arachidonic acid metabolized through these inflammatory pathways, and the prostaglandin and leukotriene output decreases. The low-amylose dietary pattern removes the amylose-driven insulin amplification from one direction while the therapeutic omega-3 supplementation attacks the inflammatory cascade from another. This is the architecture of the intervention: two targeted inputs dismantling the same inflammatory loop from opposite ends.

The proprietary concept worth naming here is the Insulin-MMP-9 Amplifier. This is the loop the diet is either feeding or starving: high-amylose food → insulin spike → NF-kB activation → MMP-9 upregulation → accelerated barrier degradation → deeper neurological symptoms → cytokine amplification → repeat. Remove the amylose input and the loop loses its primary fuel. Add therapeutic omega-3s and the existing inflammatory load starts actively dismantling. The intervention is surgical. The mechanism is clear. The biomarker verification is available at 30 days. This is not opinion. It’s documented biochemistry with clinical confirmation.

For the detailed picture of how mycotoxins affect the digestive system — the secondary inflammatory loop that also benefits from the dietary intervention — that article covers the gut-specific mechanisms in depth.

The Protocol: Exactly What to Eliminate, Eat, and Supplement

No hedging. No vague guidance. Here’s the operational protocol, built on the Shoemaker clinical framework and the mechanistic evidence reviewed above. This is what to do.

The elimination list — remove these completely for 30 days minimum:

• All bread — white, whole wheat, sourdough, rye, gluten-free varieties made with rice, corn, tapioca, or potato flour
• All rice — white, brown, wild rice in quantities above a few tablespoons
• White potatoes in all forms — baked, mashed, fried, roasted, any preparation
• Corn in all forms — tortillas, corn chips, polenta, grits, cornbread, popcorn
• All pasta — regular, whole wheat, and so-called healthy alternatives made with high-starch flours
• Oats, cereals, granola, and any grain-based breakfast food
• Beer (liquid bread — barley malt plus high-glycemic carbohydrates)
• Crackers and rice cakes in all varieties
• Most commercial sauces and condiments (starch thickeners are in most of them — read labels)
• Anything labeled “gluten-free” that contains rice flour, corn flour, tapioca starch, or potato starch — the gluten is irrelevant; the amylose is the target

The five primary vehicles — bread, rice, white potatoes, corn, pasta — account for the overwhelming majority of dietary amylose in a standard Western eating pattern. Eliminate those five and roughly 90 percent of the intervention is done. Don’t spend the first week auditing every ingredient in every condiment. Get the five major categories out first. Tighten the peripheral sources in week two once the primary habit shift has stabilized.

The replacement architecture — eat these freely:

• Proteins: Grass-fed beef, lamb, bison, pastured pork and chicken, turkey. Wild-caught fatty fish — salmon, sardines, mackerel, anchovies, herring — at minimum three to four servings per week; these do double duty as both protein source and omega-3 delivery vehicle. Pastured eggs in any preparation. Wild-caught shellfish: oysters particularly, since their zinc content supports the enzymatic activity inflamed tissues need for repair. These proteins provide the amino acid backbone for tissue repair and the saturated and monounsaturated fats replacing the energy density lost by eliminating starch.
• Fats: Extra virgin olive oil as the primary cooking fat — calorie-dense and rich in oleocanthal, a compound with documented NF-kB inhibiting activity. Avocados and avocado oil. Coconut oil for high-heat cooking. Butter or ghee from pastured cows. Walnuts, almonds, macadamia nuts, pecans — a generous handful at a time. Full-fat coconut milk for cooking. These fats are not optional additions. They’re the caloric backbone that sustains the body while the starch calories are gone. Follow this protocol while also restricting fat out of habit or fear, and perpetual hunger, cognitive impairment, and non-compliance by day eight are the likely outcome. Eat the fat.
• Vegetables: All non-starchy vegetables, freely. Leafy greens — spinach, arugula, kale, Swiss chard, romaine. Cruciferous vegetables — broccoli, cauliflower, Brussels sprouts, cabbage — particularly the cruciferous family, since these provide the indole-3-carbinol that supports Phase I liver detoxification of mycotoxins. Peppers, zucchini, cucumber, celery, asparagus, green beans, mushrooms, onions, garlic, leeks. Sweet potatoes are permitted two to three times per week in moderate portions — lower glycemic index than white potatoes, beta-carotene for antioxidant support, and a useful psychological relief valve during the first weeks when the eliminated starches are still calling. Lentils and black beans in moderate portions are generally well-tolerated unless gut inflammation is severe, in which case introduce them slowly in week two.
• Fruits: Berries of all types, green apples, citrus fruits, kiwi — low-glycemic and rich in polyphenols with documented anti-inflammatory activity. High-sugar fruits like bananas, mangoes, and grapes are not prohibited but keep them to small servings. The fructose load from moderate fruit consumption does not spike insulin the same way glucose does, but moderation is appropriate while metabolic regulation is still recovering.

The omega-3 protocol — specific doses, specific timing:

The Shoemaker protocol specifies 2.4g EPA plus 1.8g DHA daily — 4.2g combined EPA/DHA. A therapeutic dose, not the amount in a standard fish oil capsule. A typical 1,000mg fish oil softgel contains approximately 180mg EPA and 120mg DHA. Roughly 13 standard softgels daily would be needed to reach the therapeutic target. That arithmetic alone says product selection isn’t a casual decision.

Which is the argument for a concentrated, pharmaceutical-grade product over a commodity softgel. Triglyceride-form omega-3s are preferred over ethyl ester forms — the triglyceride form has 30 to 50 percent superior bioavailability. Molecular distillation for purity and third-party IFOS (International Fish Oil Standards) certification for mercury, PCBs, and dioxins are non-negotiable criteria.

CIRS patients have compromised detoxification capacity. Introducing additional environmental contaminants via substandard fish oil is a poor trade.

Split the daily dose between two fat-containing meals. Taking fish oil with food increases absorption by 30 to 50 percent compared to taking it on an empty stomach. Half the daily dose at breakfast or lunch, the other half at dinner. Fish oil burps an issue? Switch to enteric-coated softgels or store them in the freezer — frozen softgels dissolve further down the GI tract with minimal reflux.

Glutathione precursors: kitchen-level biochemistry at zero additional cost.

Biotoxin illness depletes glutathione — the body’s master antioxidant and primary Phase II liver detoxification molecule — through chronic oxidative stress and ongoing mycotoxin conjugation. Supporting glutathione synthesis through diet amplifies the clearance capacity being built with binder therapy. Eat sulfur-rich vegetables daily: garlic, onions, leeks, shallots, and cruciferous vegetables provide the cysteine precursors for glutathione synthesis. Use turmeric and black pepper together whenever cooking with heat — the piperine in black pepper increases curcumin bioavailability by up to 2,000 percent, and curcumin is a documented NF-kB inhibitor that directly addresses the transcription factor driving both MMP-9 elevation and cytokine amplification. A tablespoon of turmeric in a fat-containing meal with a pinch of black pepper is not a wellness affectation. It’s a direct NF-kB intervention delivered via spice rack.

Bone broth for gut barrier repair:

CIRS-driven inflammation damages the intestinal lining, increasing gut permeability and allowing mycotoxins and bacterial endotoxins to cross into systemic circulation, further amplifying the inflammatory load. Bone broth simmered 12 to 24 hours from pastured or grass-fed bones provides L-glutamine (primary fuel for intestinal enterocytes), collagen and gelatin (structural proteins for intestinal barrier integrity), and glycine (anti-inflammatory amino acid with sleep-supporting properties documented in human trials). Two cups daily, consumed as a warm beverage or as the base for soups built from the approved ingredients, provides meaningful barrier support as a direct adjunct to the anti-inflammatory dietary protocol. The mold-driven inflammation and disease cycle has a gut component that this addresses directly.

The 30-day verification framework:

Get a baseline blood draw before any dietary or supplementation changes. At minimum: MMP-9, VEGF, fasting insulin, fasting glucose. If the physician is running the full Shoemaker panel, add C4a, TGF-beta 1, and HbA1c. Recheck at exactly 30 days of strict compliance. The targets: MMP-9 trending toward or below 332 ng/mL, VEGF trending toward or above 31 pg/mL, fasting insulin below 10 uIU/mL. MMP-9 hasn’t moved at all at day 30 — not trending down, literally unchanged — investigate compliance, product quality, and potential ongoing environmental exposures before concluding the protocol is ineffective. Some patients with very elevated baseline MMP-9 require 60 to 90 days of strict compliance before reaching the target range. Absence of complete normalization at day 30 is not failure. Zero movement is a signal to investigate. Meaningful movement is a signal to continue.

The Proof: LowAmylose Diet Starving: What The Evidence Reveals

The evidence base for the low-amylose dietary intervention in CIRS comes from multiple streams of research. There is no single randomized controlled trial studying this diet specifically in CIRS patients — the condition is too heterogeneous, the patient population too medically complex, and mainstream medicine’s engagement with CIRS too limited for that kind of study to have been conducted. What exists is a mechanistically coherent evidence base built from clinical outcome data, inflammation research, and metabolic studies that together support every piece of the intervention.

• Shoemaker’s clinical outcomes database. Dr. Ritchie Shoemaker’s published work — including case series and outcomes data presented across his books, peer-reviewed papers co-authored with researchers including Dennis House and published in journals including Toxicology and Industrial Health — identifies the dietary intervention as a critical determinant of MMP-9 and VEGF normalization timelines. His clinical database of thousands of treated CIRS patients consistently shows that patients who implement the full protocol including dietary changes normalize biomarkers faster than patients who execute every other step but continue eating high-amylose foods. Not a randomized controlled trial. Also not anecdote. A consistent observation replicated across thousands of patients and documented in clinical records is meaningful evidence in a disease category mainstream research has largely ignored. The absence of a gold-standard RCT does not make the clinical evidence invisible. It makes it the best available data — which is precisely how medicine operates in every specialty dealing with complex multi-system illness.
• Liu et al. (2002) — glycemic load and systemic inflammation. This study, published in the American Journal of Clinical Nutrition, examined the relationship between dietary glycemic load and inflammatory biomarkers in a population of healthy women without known inflammatory disease. The finding: higher dietary glycemic load was independently and significantly associated with elevated C-reactive protein, IL-6, and related inflammatory markers after adjustment for potential confounders. Women in the highest quintile of glycemic load had substantially higher inflammatory markers than women in the lowest quintile. The study was conducted in a population without CIRS — meaning the inflammatory amplification that high-glycemic food produces is the baseline effect in a non-dysregulated immune system. In CIRS patients, where the cytokine system is already running in a chronically activated state, the insulin-driven amplification from high-amylose meals would be expected to be more pronounced, not less. This study established the foundational mechanism at the population level.
• Post-prandial hyperinsulinemia and MMP-9 elevation. Research by Derosa et al. (2007) in the Journal of Internal Medicine and supporting mechanistic work from multiple groups established the direct relationship between post-meal insulin spikes and acute MMP-9 elevation in human subjects. The mechanism: insulin activates NF-kB, the master transcription factor for inflammatory gene expression, which drives upregulation of the MMP-9 gene. The effect is acute — measurable within two to four hours of a high-carbohydrate meal — meaning each high-amylose meal in a CIRS patient produces a near-immediate, documented elevation in the enzyme responsible for blood-brain barrier degradation, connective tissue destruction, and vascular wall damage. Not a chronic background effect. A meal-driven event occurring predictably, acutely, and repeatedly in every CIRS patient eating a standard Western diet while following the rest of the protocol.
• The PREDIMED trial (2013) — Mediterranean diet and inflammatory reduction. The Prevención con Dieta Mediterránea trial, published in the New England Journal of Medicine and enrolling over 7,400 participants at high cardiovascular risk, compared a Mediterranean-pattern diet (high in olive oil, nuts, fatty fish, and non-starchy vegetables — precisely the foods that characterize the low-amylose replacement architecture) against a low-fat control diet. The Mediterranean arm produced significant reductions in IL-6, CRP, and other systemic inflammatory markers, in addition to the 30 percent reduction in major cardiovascular events that made the trial famous. The inflammatory biomarker data from PREDIMED are directly applicable to the mold diet protocol because the foods that drove the anti-inflammatory effect in PREDIMED are the foods that fill the dietary gap when high-amylose staples are eliminated.
• Calder (2006) — omega-3 meta-analysis. This meta-analysis, published in the American Journal of Clinical Nutrition and reviewing over 30 randomized controlled trials of fish oil supplementation, found consistent, dose-dependent reductions in TNF-alpha, IL-1 beta, and IL-6 with EPA/DHA supplementation at doses above 2g combined daily. These are the specific cytokines that CIRS dysregulates. The dose-response relationship is important: at 1g combined EPA/DHA, the effect is modest and variable. At 3-4g combined EPA/DHA, the effect is strong and consistent across study populations. The Shoemaker protocol’s 4.2g combined daily target sits at the high end of the therapeutic dose range precisely because the CIRS cytokine burden is substantially higher than the general inflammatory conditions studied in most omega-3 RCTs.
• Serhan and Petasis (2011) — resolvin and protectin mechanisms. Published in Chemical Reviews, this mechanistic review documented the specific lipid mediators derived from EPA and DHA — resolvins and protectins — that actively terminate inflammatory cascades rather than merely suppressing their amplitude. Resolvin E1 and protectin D1 have been shown to inhibit neutrophil migration to inflammatory sites, reduce cytokine production from macrophages, and stimulate phagocytosis of cellular debris — the process of clearing the tissue damage that inflammation has produced. In CIRS, where the inflammatory cascade has been running for months or years, the capacity to resolve rather than just suppress inflammation is therapeutically meaningful. The EPA/DHA supplementation component of the protocol is providing active resolution signals, not just an anti-inflammatory dampener.

The evidence, taken together, supports a mechanistically coherent case grounded in peer-reviewed human research at every step. The specific CIRS-and-diet RCT has not been conducted. The mechanism it would be testing has been established in human subjects by the research that has been conducted. The clinical observation consistent with that mechanism has been documented across thousands of treated patients. A solid foundation for a dietary intervention in a condition where the alternative — continuing to eat high-amylose foods while wondering why MMP-9 won’t drop — is demonstrably counterproductive.

The Mistakes: Five Ways People Sabotage This Protocol

Knowing the protocol is not the same as executing it without the common failure modes. These are the five specific traps that derail CIRS patients attempting the dietary intervention, ranked roughly by frequency. Read them before starting. Read them again two weeks in with no improvement to show for it.

Mistake 1: The gluten-free trap. This one sends people sideways more than any other single error. The gluten-free product industry has built an entire category of foods that replace wheat flour with rice flour, corn flour, tapioca starch, and potato starch — all high-amylose carbohydrates. A gluten-free cracker made with rice flour produces an insulin response comparable to a conventional cracker. The MMP-9 amplification event is comparable. The blood-brain barrier degradation is comparable. The difference between the gluten-free cracker and the regular cracker is the absence of a protein — gluten — that isn’t the variable being controlled here. Not even adjacent to it. CIRS patients who eat “gluten-free” as a substitute for “low-amylose” are making a category error with consequences in their biomarkers that show up at the 30-day recheck. Read labels. Rice, corn, potato, or tapioca in any form means it doesn’t belong in the 30-day intervention window.

Mistake 2: Hidden amylose in commercial foods. Starch thickeners appear in commercial sauces, condiments, salad dressings, canned soups, pre-marinated proteins, and most “healthy” packaged foods. Soy sauce typically contains wheat. Teriyaki sauce contains modified food starch. Most bottled salad dressings contain corn starch or rice flour. Canned soup is essentially starch delivery in liquid form. Regular packaged or restaurant food during the 30-day intervention almost guarantees meaningful, untracked amylose consumption. The solution isn’t food paranoia. It’s cooking from whole ingredients — entirely practical given the approved food list — during the intervention window. Restaurants are difficult but not impossible: order protein and vegetables, specify no sauce or ask for sauce on the side and check the ingredient profile, skip the bread basket and side starch automatically. This protocol is executable while traveling and eating in restaurants. It requires about 30 seconds of awareness per meal, not a packed cooler and a laminated card.

Mistake 3: Weekend compliance gaps. A single high-amylose meal can spike insulin and re-elevate MMP-9 within two to four hours. The inflammatory amplification event is acute. Which means the compliance model for this protocol is not 80/20. Five days of strict adherence followed by a Saturday night pizza does not produce five-sevenths of the benefit. It produces partial benefit interrupted by a weekly re-triggering of the insulin-NF-kB-MMP-9 cascade, which takes several days to return to the suppressed baseline. The math is punishing: by the time recovery from the Saturday spike is complete, the next weekend is nearly here. Biomarkers at day 30 reflect an inflammatory average that includes the weekly re-amplification events, and they will look accordingly disappointing. Thirty days of strict compliance is the minimum effective dose. Can’t commit to 30 consecutive days of strict adherence? Wait until it’s possible. Starting a protocol that won’t be executed properly is not better than not starting it. It’s worse, because it produces false information about whether the intervention works.

Mistake 4: Under-eating fat. Decades of low-fat dietary conditioning have trained most people’s instincts to avoid dietary fat. When the primary caloric staples — bread, rice, potatoes, pasta — are removed, the default response for many people is to eat the same meal minus the starch and end up with 600-700 calories when 1,800 are needed. The result is inadequate caloric intake, fatigue, irritability, and cognitive impairment — symptoms indistinguishable from CIRS worsening, which produces demoralization and protocol abandonment. The low-amylose eating pattern is not caloric restriction. It’s macronutrient restructuring. The calories removed as starch must be replaced as fat and protein. One tablespoon of olive oil is 120 calories. Half an avocado is 120 calories. A handful of macadamia nuts is 200 calories. A salmon fillet cooked in olive oil is 350-400 calories. Build the plate with these as central elements and there will be enough to eat. Treat fat as an add-on garnish, and hunger-driven failure arrives within a week, followed by the conclusion that the protocol is unsustainable — yet another diet that “didn’t work.”

Mistake 5: Substandard fish oil. A 2010 analysis published in Cardiovascular Therapeutics tested 48 commercially available fish oil products and found that 31 percent contained less than 90 percent of their labeled EPA/DHA content. Some products were substantially below label. Buying a budget fish oil capsule at a grocery store to hit the 2.4g EPA / 1.8g DHA therapeutic target means the probability of actually hitting that target is below 70 percent. At the Shoemaker protocol doses, this matters: the difference between 2.4g EPA and 1.2g EPA is the difference between therapeutic resolution activity and a modest anti-inflammatory effect that won’t move CIRS biomarkers. Use the IFOS database — publicly accessible online — to verify a product has been independently tested for potency, freshness, and purity before buying. Molecular distillation for heavy metal removal is standard practice in quality products; absent documentation about distillation is a red flag. The fish oil component of this protocol is not where to economize.

There’s also a psychological failure mode worth naming: the first week of dietary restructuring is genuinely uncomfortable. The hunger signals that arise when bread, rice, and pasta disappear are real even when caloric intake is adequate — they’re the withdrawal of an insulin-driven metabolic rhythm the body has been running for years. The cycle of post-meal insulin spikes and subsequent hunger signals is a physiological loop, and breaking it produces real hunger and cognitive craving for the first five to seven days. Expecting this, and understanding its source, makes it possible to persist through it. Most patients find that by day seven to ten, afternoon energy has stabilized, post-meal cognitive crashes have diminished, and the contrast with the previous pattern is itself motivating. The discomfort is front-loaded. The benefit compounds. Persist through the first week.

Common Questions About LowAmylose Diet Starving About the Low-Amylose Diet for Mold Inflammation

Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map